Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
06 9월 2023 - 8:03PM
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage
biotechnology company developing therapies for patients with kidney
disease (the “Company” or “Unicycive”), today announced the
appointment of Sara Kenkare-Mitra, PhD to the Company’s Board of
Directors, effective September 6, 2023. As a veteran of the biotech
and pharmaceutical industry, we believe Sara’s leadership and
experience in drug development spanning more than 25 years will
significantly help bolster Unicycive’s future growth.
“We are thrilled to welcome Dr. Kenkare-Mitra to
our Board of Directors and know that her extensive drug development
and corporate leadership experience will make an immediate impact
here at Unicycive,” said Shalabh Gupta, MD, Chief Executive
Officer. “Sara adds a broad skill set to our Board with leadership
expertise spanning research, preclinical and clinical development,
translational medicine, manufacturing, and regulatory. Importantly,
she has played a key role in the filing of more than 100
investigational new drug (IND) and clinical trial applications and
worked on 11 drug approvals in multiple diseases. Sara’s
appointment comes at a crucial time for Unicycive as we advance
oxylanthanum carbonate towards filing of a new drug application and
prepare to file an IND for UNI-494.”
Dr. Kenkare-Mitra, added, “I am honored to join
the Unicycive Board of Directors to help advance the company’s
purpose-driven strategy to solve the most pressing unmet medical
needs in renal diseases. I look forward to helping Unicycive with
my expertise and experience in preclinical and clinical development
and navigating the regulatory landscape as the organization
advances their assets.”
Sara Kenkare-Mitra, PhD is currently President
and Head of Research and Development at Alector where she leads all
aspects of the company’s R&D efforts in neurodegeneration,
including oversight of the research, development, clinical,
manufacturing, regulatory, and related functions. Prior to joining
Alector, Dr. Kenkare-Mitra held roles of increasing responsibility
at Genentech over the course of 23 years serving most recently as
Senior Vice President, Development Sciences in Genentech’s research
and early development unit. During her tenure at Genentech, she led
a large, integrated global organization of approximately 650
employees, and played a key role in the filing of more than 100
Investigational New Drug (IND)/clinical trial applications around
the world, and the approval of 11 medicines for diverse diseases,
including cancers and neurological diseases. Her team also enabled
the successful development and approval of over 15 companion
diagnostics.
Dr. Kenkare-Mitra received her PhD in
Pharmaceutical Chemistry from the University of California, San
Francisco (UCSF), where she also stayed on as a Post-Doctoral
Fellow in the school of medicine and also completed a Fellowship in
Clinical Pharmacology before joining Genentech. Dr.
Kenkare-Mitra also holds adjunct faculty positions in the
Department of Bioengineering and Therapeutic Sciences at UCSF and
at the University of the Pacific in Stockton. She is an
elected member of the National Academy of Medicine (NAM) and
elected fellow of Association for the Advancement of Science
(AAAS). She has been widely recognized for her work and leadership
in the industry with awards such as the American Association of
Pharmaceutical Scientists’ Alice E. Till Advancement of Women in
Pharmaceutical Sciences Recognition, Endpoints’ 20 Most
Extraordinary Women in Biopharma, Fierce Pharma’s Fiercest Women in
the Life Sciences, and the University of California, San
Francisco’s Distinguished Alumnus of the Year. She has served as a
board member of the Genentech foundation and the Association of
Women in Science (AWIS).
About Unicycive
Therapeutics
Unicycive Therapeutics is a biotechnology
company developing novel treatments for kidney diseases.
Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a
novel investigational phosphate binding agent being developed for
the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis. UNI-494 is a patent-protected new chemical
entity in late preclinical development for the treatment of acute
kidney injury. For more information, please visit
Unicycive.com.
Forward-looking statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
using words such as "anticipate," "believe," "forecast,"
"estimated" and "intend" or other similar terms or expressions that
concern Unicycive's expectations, strategy, plans or intentions.
These forward-looking statements are based on Unicycive's current
expectations and actual results could differ materially. There are
several factors that could cause actual events to differ materially
from those indicated by such forward-looking statements. These
factors include, but are not limited to, clinical trials involve a
lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of
future trial results; our clinical trials may be suspended or
discontinued due to unexpected side effects or other safety risks
that could preclude approval of our product candidates; risks
related to business interruptions, which could seriously harm our
financial condition and increase our costs and expenses; dependence
on key personnel; substantial competition; uncertainties of patent
protection and litigation; dependence upon third parties; and risks
related to failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the
uncertainties related to market conditions and other factors
described more fully in the section entitled ‘Risk Factors’ in
Unicycive’s Annual Report on Form 10-K for the year ended December
31, 2022, and other periodic reports filed with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Unicycive
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor Contact:
ir@unicycive.com(650) 900-5470
SOURCE: Unicycive Therapeutics, Inc.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/4ea83c39-297b-44d4-9129-e4fed5de58cb
Unicycive Therapeutics (NASDAQ:UNCY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Unicycive Therapeutics (NASDAQ:UNCY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024